BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14594511)

  • 1. Standardization of the CFU-GM assay: Advantages of plating a fixed number of CD34+ cells in collagen gels.
    Dobo I; Pineau D; Robillard N; Geneviève F; Piard N; Zandecki M; Hermouet S
    J Hematother Stem Cell Res; 2003 Oct; 12(5):543-51. PubMed ID: 14594511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating stem cell collection in lymphoma and myeloma after mobilization with cyclophosphamide and granulocyte colony-stimulating factor for autologous transplantation.
    Cancelas JA; Hernández-Jodra M; Zamora C; Perez-Oteyza J; Brieva JA; Roldan E; Navas G; Garcia-Laraña J; Lopez J; Odriozola J
    Vox Sang; 1994; 67(4):362-7. PubMed ID: 7535498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
    Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
    Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducible scoring of CFU-GM and BFU-E grown in collagen-based semisolid medium after a short (3 h) training.
    Dobo I; Bidet JM; Acquart S; Allegraud A; Amiot L; Boccaccio C; Boiret N; Domenech J; Mossuz P; Sensebe L; Wunder E; Zandecki M; Hermouet S
    J Hematother; 1999 Feb; 8(1):45-51. PubMed ID: 10192301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plastic-adherent progenitor cells in mobilized peripheral blood progenitor cell collections.
    Scott MA; Apperley JF; Jestice HK; Bloxham DM; Marcus RE; Gordon MY
    Blood; 1995 Dec; 86(12):4468-73. PubMed ID: 8541535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
    Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
    J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses.
    Dobo I; Robillard N; Pineau D; Geneviève F; Piard N; Rapp MJ; Boasson M; Zandecki M; Hermouet S
    Ann Hematol; 2001 Nov; 80(11):639-46. PubMed ID: 11757722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.
    Siena S; Bregni M; Brando B; Belli N; Ravagnani F; Gandola L; Stern AC; Lansdorp PM; Bonadonna G; Gianni AM
    Blood; 1991 Jan; 77(2):400-9. PubMed ID: 1702334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
    Hermouet S; Niaussat AE; Briec A; Pineau D; Robillard N; Bataille R; Milpied N; Harousseau JL; Mahé B
    Hematol Cell Ther; 1997 Dec; 39(6):317-25. PubMed ID: 9497891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations among white blood cells, CD34+ cells and GM-CFU in predicting the optimal timing of peripheral blood stem cell collections by apheresis.
    Boulassel MR
    J Assoc Physicians India; 2008 Feb; 56():96-8. PubMed ID: 18472508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the CD34+ and CD34+Thy-1+ stem cell content of peripheral blood collections.
    Stewart AK; Imrie K; Keating A; Anania S; Nayar R; Sutherland DR
    Exp Hematol; 1995 Dec; 23(14):1619-27. PubMed ID: 8542956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation.
    Decot V; Alla F; Latger-Cannard V; Visanica S; Witz B; Stoltz JF; Bensoussan D
    Biomed Mater Eng; 2012; 22(1-3):57-67. PubMed ID: 22766703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
    J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cultures to evaluate engraftment potential of CD34+ cells from peripheral blood after mobilization by chemotherapy with and without GM-CSF.
    Benboubker L; Domenech J; Linassier C; Desbois I; Delain M; Lamagnere JP; Colombat P; Binet C
    Exp Hematol; 1995 Dec; 23(14):1568-73. PubMed ID: 8542948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?
    Jansen EM; Hanks SG; Terry C; Akard LP; Thompson JM; Dugan MJ; Jansen J
    Transfusion; 2007 May; 47(5):817-23. PubMed ID: 17465946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.